GLEEVEC IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是评价格列卫的临床反应。 次要目的是评价免疫组化测定的PDGF受体抑制;评价伊马替尼治疗前后的细胞因子谱;评价伊马替尼在HIV患者中的药代动力学特征;评价伊马替尼治疗的原发性和继发性耐药机制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to evaluate the clinical response of Gleevec. The secondary objectives are to evaluate the inhibition of PDGF receptor as determined by immunohistochemistry; to evaluate cytokine profiles pre and post imatinib therapy; to evaluate the pharmacokinetic profile of imatinib in HIV patients; and to evaluate the mechanisms of primary and secondary resistance to imatinib therapy.